High-Density Lipoprotein Cholesterol as a Risk Factor and Target of Therapy after Acute Coronary Syndrome

American Journal of Cardiology

Volumn 104, Issue 10 SUPPL., 2009, Pages 46E-51E

  Schwartz, Gregory G ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; APOLIPOPROTEIN A1; ATORVASTATIN; CSL 111; DALCETRAPIB; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PIOGLITAZONE; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART MUSCLE; HEMOSTASIS; HUMAN; HYPOTHESIS; INFLAMMATION; INTRAVASCULAR ULTRASOUND; ISCHEMIA; LIPOPROTEIN BLOOD LEVEL; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; STROKE; THROMBOSIS; VASCULAR CAPACITY;

EID: 71849117483     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.09.019     Document Type: Article

References (46)

1. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., Ford E., Furie K., Go A., Greenlund K., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) e21-e181
2. O'Donoghue M., Boden W.E., Braunwald E., Cannon C.P., Clayton T.C., de Winter R.J., Fox K.A., Lagerqvist B., McCullough P.A., Murphy S.A., et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 300 (2008) 71-80
3. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
4. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
5. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
6. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 62 (1977) 707-714
7. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Munster study. Am J Cardiol 70 (1992) 733-737
8. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345 (1995) 1274-1275
9. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
11. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
12. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., Kastelein J.J., Bittner V., and Fruchart J.C. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
13. Tardif J.C., McMurray J.J., Klug E., Small R., Schumi J., Choi J., Cooper J., Scott R., Lewis E.F., L'Allier P.L., and Pfeffer M.A. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 1761-1768
14. de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A., White H.D., Rouleau J.L., Pedersen T.R., Gardner L.H., Mukherjee R., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
15. Sachdeva A., Cannon C.P., Deedwania P.C., Labresh K.A., Smith Jr. S.C., Dai D., Hernandez A., and Fonarow G.C. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 157 (2009) 111-117
16. Olsson A.G., Schwartz G.G., Szarek M., Sasiela W.J., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., and Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 26 (2005) 890-896
17. Wolfram R.M., Brewer H.B., Xue Z., Satler L.F., Pichard A.D., Kent K.M., and Waksman R. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 98 (2006) 711-717
18. Tziakas D.N., Chalikias G.K., Kaski J.C., Kekes A., Hatzinikolaou E.I., Stakos D.A., Tentes I.K., Kortsaris A.X., and Hatseras D.I. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis 193 (2007) 196-203
19. Ray K.K., Cannon C.P., Cairns R., Morrow D.A., Ridker P.M., and Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29 (2009) 424-430
20. Tall A.R. The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. Am J Cardiol 104 suppl 10A (2008) 39E-45E
21. Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 33 (2004) 393-403
22. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
23. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., Kouz S., Berry C., Basser R., Lavoie M.A., Guertin M.C., and Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682
24. Sacks F.M., Rudel L.L., Conner A., Akeefe H., Kostner G., Baki T., Rothblat G., de la Llera-Moya M., Asztalos B., Perlman T., et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 50 (2009) 894-907
25. Waksman R., Kent K., Pichard A., Suddath W., Satler L., Martin D., Perlman T., Richardson D., Maltais J.A., Landry P., et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high density lipoprotein plasma infusions in patients with acute coronary syndrome. Circulation 118 suppl 2 (2009) S371
26. Esper R.J., Vilarino J., Cacharron J.L., Machado R., Ingino C.A., Garcia Guinazu C.A., Bereziuk E., Bolano A.L., Suarez D.H., and Kura M. Impaired endothelial function in patients with rapidly stabilized unstable angina: assessment by noninvasive brachial artery ultrasonography. Clin Cardiol 22 (1999) 699-703
27. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., Corti R., Ruschitzka F., Luscher T.F., and Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
28. Imazu M., Ono K., Tadehara F., Kajiwara K., Yamamoto H., Sumii K., Tasaki N., Oiwa J., Shimohara Y., Gomyo Y., and Itabe H. Plasma levels of oxidized low density lipoprotein are associated with stable angina pectoris and modalities of acute coronary syndrome. Int Heart J 49 (2008) 515-524
29. Johnston N., Jernberg T., Lagerqvist B., Siegbahn A., and Wallentin L. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol 113 (2006) 167-173
30. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 473-480
31. Brambilla M., Camera M., Colnago D., Marenzi G., De Metrio M., Giesen P.L., Balduini A., Veglia F., Gertow K., Biglioli P., and Tremoli E. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol 28 (2008) 947-953
32. Davi G., and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357 (2007) 2482-2494
33. Viswambharan H., Ming X.F., Zhu S., Hubsch A., Lerch P., Vergeres G., Rusconi S., and Yang Z. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 94 (2004) 918-925
34. Mineo C., Deguchi H., Griffin J.H., and Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 98 (2006) 1352-1364
35. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., and Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 347 (2002) 5-12
36. Puranik R., Bao S., Nobecourt E., Nicholls S.J., Dusting G.J., Barter P.J., Celermajer D.S., and Rye K.A. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 196 (2008) 240-247
37. Theilmeier G., Schmidt C., Herrmann J., Keul P., Schafers M., Herrgott I., Mersmann J., Larmann J., Hermann S., Stypmann J., et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114 (2006) 1403-1409
38. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., La Du B.N., Fogelman A.M., and Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96 (1995) 2758-2767
39. Ansell B.J., Navab M., Hama S., Kamranpour N., Fonarow G., Hough G., Rahmani S., Mottahedeh R., Dave R., Reddy S.T., and Fogelman A.M. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108 (2003) 2751-2756
40. Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). http://www.clinicaltrials.gov/ct2/show/NCT00461630?term=NCT00461630& rank=1
41. Niacin Plus Statin to Prevent Vascular Events. http://www.clinicaltrials.gov/ct2/show?term=NCT00120289&rank=1
42. Action to Control Cardiovascular Risk in Diabetes (ACCORD). http://www.clinicaltrials.gov/ct2/show/NCT00000620?term=NCT00000620& rank=1
43. Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study). http://www.clinicaltrials.gov/ct2/show/NCT00212004?term=NCT00212004& rank=1
44. Insulin Resistance Intervention After Stroke Trial (IRIS). http://www.clinicaltrials.gov/ct2/show/NCT00091949?term=NCT00091949& rank=1
45. A Study of RO4607381 in Stable Coronary Heart Disease Patients with Recent Acute Coronary Syndrome. http://www.clinicaltrials.gov/ct2/show/NCT00658515?term=NCT00658515& rank=1
46. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., van T.A., and Kastelein J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165